PDE3B and neoplasm: In non-diabetic women with operable stage I/II breast cancer, short-term neoadjuvant treatment with metformin, although not affecting tumor size, led to decreased Ki67 and phosphodiesterase 3 (PDE3B) staining in postoperative samples.